|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9295
|
|
pubmed:dateCreated |
2001-12-5
|
|
pubmed:abstractText |
Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalises insulin-like growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0140-6736
|
|
pubmed:author |
pubmed-author:BarlowC FCF,
pubmed-author:BesserG MGM,
pubmed-author:ClemmonsD RDR,
pubmed-author:CookD MDM,
pubmed-author:DavisR JRJ,
pubmed-author:FredaP UPU,
pubmed-author:FriendK EKE,
pubmed-author:HackettSS,
pubmed-author:Herman-BonertVV,
pubmed-author:HutsonR KRK,
pubmed-author:JohannssonGG,
pubmed-author:KatznelsonLL,
pubmed-author:KlibanskiAA,
pubmed-author:MelmedSS,
pubmed-author:PhillipsL SLS,
pubmed-author:ScarlettJ AJA,
pubmed-author:StavrouSS,
pubmed-author:StewartP MPM,
pubmed-author:StrasburgerC JCJ,
pubmed-author:ThornerM OMO,
pubmed-author:TrainerP JPJ,
pubmed-author:VanceM LML,
pubmed-author:ZhuK MKM,
pubmed-author:van der LelyA JAJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
24
|
|
pubmed:volume |
358
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1754-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11734231-Acromegaly,
pubmed-meshheading:11734231-Adult,
pubmed-meshheading:11734231-Blood Glucose,
pubmed-meshheading:11734231-Cohort Studies,
pubmed-meshheading:11734231-Drug Administration Schedule,
pubmed-meshheading:11734231-Female,
pubmed-meshheading:11734231-Growth Hormone,
pubmed-meshheading:11734231-Human Growth Hormone,
pubmed-meshheading:11734231-Humans,
pubmed-meshheading:11734231-Insulin,
pubmed-meshheading:11734231-Insulin-Like Growth Factor I,
pubmed-meshheading:11734231-Male,
pubmed-meshheading:11734231-Middle Aged,
pubmed-meshheading:11734231-Receptors, Somatotropin
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.
|
|
pubmed:affiliation |
Erasmus Medical Centre Rotterdam, 40 Dr Molewaterplein, 3015 GD, Rotterdam, Netherlands. vanderlely@inw3.azr.nl
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
